145 related articles for article (PubMed ID: 15257317)
1. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation.
Mhawech P; Benz A; Cerato C; Greloz V; Assaly M; Desmond JC; Koeffler HP; Lodygin D; Hermeking H; Herrmann F; Schwaller J
Mod Pathol; 2005 Mar; 18(3):340-8. PubMed ID: 15257317
[TBL] [Abstract][Full Text] [Related]
2. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
3. 14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.
Schultz J; Ibrahim SM; Vera J; Kunz M
Mol Cancer; 2009 Jul; 8():53. PubMed ID: 19642975
[TBL] [Abstract][Full Text] [Related]
4. Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.
Motokura T; Nakamura Y; Sato H
BMC Cancer; 2007 Nov; 7():217. PubMed ID: 18036248
[TBL] [Abstract][Full Text] [Related]
5. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
Lodygin D; Diebold J; Hermeking H
Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis.
Luo J; Feng J; Lu J; Wang Y; Tang X; Xie F; Li W
Med Oncol; 2010 Sep; 27(3):791-7. PubMed ID: 19685192
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
Sidiropoulos M; Pampalakis G; Sotiropoulou G; Katsaros D; Diamandis EP
Tumour Biol; 2005; 26(6):324-36. PubMed ID: 16254462
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of the cell type-specific gene 14-3-3sigma.
Oshiro MM; Futscher BW; Lisberg A; Wozniak RJ; Klimecki WT; Domann FE; Cress AE
Neoplasia; 2005 Sep; 7(9):799-808. PubMed ID: 16229802
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Horie-Inoue K; Inoue S
Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214
[TBL] [Abstract][Full Text] [Related]
11. Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation.
Lal G; Padmanabha L; Provenzano M; Fitzgerald M; Weydert J; Domann FE
Cancer Lett; 2008 Aug; 267(1):165-74. PubMed ID: 18440129
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers.
Suzuki H; Itoh F; Toyota M; Kikuchi T; Kakiuchi H; Imai K
Cancer Res; 2000 Aug; 60(16):4353-7. PubMed ID: 10969776
[TBL] [Abstract][Full Text] [Related]
13. The role of epigenetic inactivation of 14-3-3sigma in human cancer.
Lodygin D; Hermeking H
Cell Res; 2005 Apr; 15(4):237-46. PubMed ID: 15857578
[TBL] [Abstract][Full Text] [Related]
14. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
[TBL] [Abstract][Full Text] [Related]
15. Loss of 14-3-3sigma in prostate cancer and its precursors.
Cheng L; Pan CX; Zhang JT; Zhang S; Kinch MS; Li L; Baldridge LA; Wade C; Hu Z; Koch MO; Ulbright TM; Eble JN
Clin Cancer Res; 2004 May; 10(9):3064-8. PubMed ID: 15131044
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.
Akahira J; Sugihashi Y; Suzuki T; Ito K; Niikura H; Moriya T; Nitta M; Okamura H; Inoue S; Sasano H; Okamura K; Yaegashi N
Clin Cancer Res; 2004 Apr; 10(8):2687-93. PubMed ID: 15102672
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3sigma is down-regulated in human prostate cancer.
Urano T; Takahashi S; Suzuki T; Fujimura T; Fujita M; Kumagai J; Horie-Inoue K; Sasano H; Kitamura T; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2004 Jul; 319(3):795-800. PubMed ID: 15184053
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
20. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.
Banelli B; Bonassi S; Casciano I; Mazzocco K; Di Vinci A; Scaruffi P; Brigati C; Allemanni G; Borzì L; Tonini GP; Romani M
Int J Cancer; 2010 Feb; 126(3):656-68. PubMed ID: 19626586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
